London, 08 June 2015 – Technavio has published a new report on the global restless legs syndrome market, which is expected to grow at a CAGR of 12% from 2015-2019.
Restless leg syndrome is a neurological disease marked by an overwhelming desire to move the legs, thus resulting in significant pain and disturbance of sleep patterns.
The new industry analysis report by Technavio draws attention towards the high unmet medical needs for patients suffering from this syndrome. The unknown etiology of the disease prevents the introduction of drugs that treat the exact cause of the disease, and currently marketed drugs offer only symptomatic relief.
“Adverse effects caused by the use of available drugs creates unmet needs in the market. Any drug that can provide a complete cure with minimal side effects would experience widespread adoption,” says Faisal Ghaus, Vice President of Technavio.
The latest Technavio report also emphasizes the expected entry of drugs with multiple mechanisms and novel techniques. The drugs marketed for RLS such as safinamide by Newron Pharmaceuticals appear to reduce the symptoms by novel mechanisms of action.
“Serina’s drug SER-214 involves a water-soluble polymer based drug delivery technology that can be connected to the polymer and delivered to target specific receptors,” says Ghaus.
https://www.technavio.com/%3Cp%3E%3Cstrong%3E%3Ca%20href%3D%22http%3A//ww…
